Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
August 04 2021 - 7:00AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious blood
diseases, today announced that the company will host a conference
call and live audio webcast on Wednesday, August 11, 2021, at 8:00
a.m. ET to review its second quarter 2021 financial results and
provide an update on the company.
Management will discuss the company’s progress during the
quarter, including advances in the development of omidubicel, which
has the potential to be the first approved cell therapy for blood
cancer patients in need of an allogeneic bone marrow transplant,
following the planned BLA submission in the fourth quarter of 2021.
Gamida Cell will also provide an update on its pipeline of
NAM-enabled natural killer (NK) cell therapies, including GDA-201
and genetically-modified NK cell constructs. The Company is
planning an IND submission to support the initiation of a Phase 1/2
clinical study of cryopreserved, off-the-shelf GDA-201 in patients
with follicular and diffuse large b-cell lymphomas.
The webcast will be available on the “Investors & Media”
section of the Gamida Cell website at www.gamida-cell.com. To
participate in the live call, please dial 866-930-5560 (domestic)
or 409-216-0605 (international) and refer to conference ID number
9949715. A replay of the webcast will be available approximately
two hours after the event, for approximately 30 days.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to
cures for patients with blood cancers and serious blood diseases.
We harness our cell expansion platform to create therapies with the
potential to redefine standards of care in areas of serious medical
need. For additional information, please visit www.gamida-cell.com
or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the anticipated submission of a BLA
for omidubicel and an IND for GDA-201, which statements are subject
to a number of risks, uncertainties and assumptions, including, but
not limited to Gamida Cell’s ability to prepare regulatory filings
and the review process therefor; complications in Gamida Cell’s
ability to manufacture its products; and clinical, scientific,
regulatory and technical developments. In light of these risks and
uncertainties, and other risks and uncertainties that are described
in the Risk Factors section and other sections of Gamida Cell’s
Annual Report on Form 20-F, filed with the Securities and Exchange
Commission (SEC) on March 9, 2021, as amended on March 22, 2021,
and other filings that Gamida Cell makes with the SEC from time to
time (which are available at http://www.sec.gov), the events and
circumstances discussed in such forward-looking statements may not
occur, and Gamida Cell’s actual results could differ materially and
adversely from those anticipated or implied thereby. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Gamida Cell as of
the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210804005012/en/
For investors: Stephanie Ascher Stern Investor Relations, Inc.
stephanie.ascher@sternir.com 1-212-362-1200
For media: Rhiannon Jeselonis Ten Bridge Communications
rhiannon@tenbridgecommunications.com 1-978-417-1946
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2024 to May 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From May 2023 to May 2024